For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Perspective Therapeutics (CATX) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Perspective Therapeutics is a member of our Medical group, which includes 1019 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gau ...

Financial Performance - The net loss for the three months ended March 31, 2024, was $12.3 million, or $0.02 loss per share, compared to a net loss of $0.4 million, or $0.00 per share, for the same period in 2023[21]. - The net loss from continuing operations was $11,214,000 for the three months ended June 30, 2024, compared to a loss of $9,486,000 in the same period last year[29]. - Total operating expenses for the quarter ended March 31, 2024, were $13.3 million, an increase of approximately 33% compared to $10.0 million for the same period in 2023[21]. - Total operating expenses increased to $14,789,000 for the three months ended June 30, 2024, compared to $10,342,000 in the prior year, reflecting a 43% rise[29]. Research and Development - Research and development expenses increased by approximately 127% to $7.5 million for the three months ended March 31, 2024, compared to $3.3 million for the same period in 2023[20]. - Research and development expenses for the three months ended June 30, 2024, were $9,275,000, up 72% from $5,370,000 in the same period last year[29]. - The company initiated dosing of nine patients in its Phase 1/2a study of [212Pb]VMT-α-NET, with seven patients receiving 185 MBq (5 mCi) of the treatment[3]. - The company is conducting a multi-center, open-label dose escalation study of [212Pb]VMT01 in patients with progressive MC1R-positive metastatic melanoma[8]. - The company entered a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb]VMT01 in combination with nivolumab[9]. - The company has applied for a Phase I tranche of a $400,000 grant from the National Institutes of Health to support the development of its pre-targeting program[15]. Cash and Investments - Cash, cash equivalents, and short-term investments as of March 31, 2024, were $180.6 million, compared to $9.2 million on December 31, 2023[22]. - Cash, cash equivalents, and short-term investments increased to $292,869,000 as of June 30, 2024, compared to $9,238,000 on December 31, 2023[27]. Company Growth and Future Plans - The company raised $177.2 million in gross proceeds through various financing transactions and an additional $49.5 million subsequent to March 31, 2024[1]. - Total assets rose to $385,919,000 from $97,891,000, indicating significant growth[27]. - The company expects to submit the VMT01 study amendment in the second quarter of 2024, with the first combination cohort anticipated to open shortly thereafter[25]. - The company plans to file an IND for PSV359 in late 2024, with a Phase I study expected to commence in 2025 if the study proceeds[25]. - The Somerset facility's filing is expected in the second half of 2024, aligning with the company's expansion plans[25]. - The company anticipates an increase in general and administrative expenses as it expands its headcount to support ongoing development[25]. - The company projects sufficient funding for operations and capital investments into the first quarter of 2026[25]. Administrative Expenses - General and administrative expenses decreased by approximately 12% to $5.9 million for the three months ended March 31, 2024, compared to $6.7 million for the same period in 2023[21].

Panel Discussion - Nuke 'em From Orbit: Radiotherapy Time: 9:30am ET SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will be available for one-on-one meetings with investors in the following upcoming investor conferences as well as a panel discussion as not ...

Panel Discussion - Nuke 'em From Orbit: Radiotherapy Time: 9:30am ET About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics ...

Nvidia (NASDAQ:NVDA) is having a fantastic year in the markets, up 156% in 2024. That follows a 2023 return of 239%. Surprisingly, there are a few U.S.-listed stocks outperforming Nvidia this year. Root (ROOT) Root (NASDAQ:ROOT) is up 644% year-to-date, more than 4x Nvidia's return. It's certainly been a breakout year for the Insurtech stock. In February, it reported its best Q4 results in its history and the shares gained 87% in a single week. "By investing in our differentiated technology across our three ...

SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its second quarter 2024 financial results and provide a business update on Monday, August 12, 2024 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-re ...

The mean estimate comprises four short-term price targets with a standard deviation of $5.38. While the lowest estimate of $17 indicates a 37.8% increase from the current price level, the most optimistic analyst expects the stock to surge 135% to reach $29. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. But, for CATX, an impressive average price target is not the o ...

The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and ...

SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to an updated list of additions to the membersh ...

SEATTLE, June 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will effect a 1-for-10 reverse stock split, effective at 4:01 p.m. Eastern time on June 14, 2024. Beginning with the opening of trading on June 17, 2024, Perspective's common stock is expected to begin trading on the NYSE American on a split-ad ...